C
Capricor Therapeutics D
D
CAPR
10.245
USD
-0.62
(-5.66%)
مغلق
حجم التداول
38,459
الربح لكل سهم
-1
العائد الربحي
-
P/E
-7
حجم السوق
468,276,606
الأخبار المقالات
العنوان: Capricor Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.